SCHEMBL6939770

SCHEMBL6939770

COc1cc(CNC(=O)c2cc([N+](=O)[O-])ccc2N[C@H]2CC[C@@H](O)CC2)cc(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 4/20 0.46
KMT2A Q03164 3/20 0.44
PDE7A Q13946 1/20 0.43
PDE3A Q14432 1/20 0.43
HTT P42858 3/20 0.43
ATM Q13315 1/20 0.42
PKM P14618 2/20 0.42
ALDH1A1 P00352 2/20 0.42
THRB P10828 1/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KCNMA1 Q12791 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6939768 1.00 L3MBTL1 (0.47) L3MBTL1NPSR1MAPTKMT2APDE7A
SCHEMBL6937261 0.91 GABRP (0.51) L3MBTL1NPSR1MAPTKMT2AALDH1A1
SCHEMBL6939423 0.91 GABRP (0.51) L3MBTL1NPSR1MAPTKMT2AALDH1A1
SCHEMBL6937265 0.91 GABRP (0.51) L3MBTL1NPSR1MAPTKMT2AALDH1A1
SCHEMBL6941929 0.90 MAPT (0.45) L3MBTL1NPSR1MAPTKMT2AALDH1A1
SCHEMBL6941936 0.90 MAPT (0.45) L3MBTL1NPSR1MAPTKMT2AALDH1A1
SCHEMBL6942073 0.89 NPSR1 (0.46) L3MBTL1NPSR1MAPTKMT2AHTT
SCHEMBL6942070 0.89 NPSR1 (0.46) L3MBTL1NPSR1MAPTKMT2AHTT
SCHEMBL6940791 0.87 SSTR5 (0.46) L3MBTL1NPSR1MAPTKMT2AALDH1A1
SCHEMBL6939759 0.87 LMNA (0.46) L3MBTL1NPSR1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP claimed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US claimed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN claimed
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A L3MBTL1 4716/4885NPSR1 2833/4885MAPT 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.